BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Novartis Corporation (NVS) Pulls Zelnorm Off The Market


3/30/2007 5:49:45 PM

March 30, 2007 -- Novartis suspended sales of Zelnorm, a treatment for irritable bowel syndrome, because of angina pectoris side effects; an FDA advisory panel recommended approval for Provenge, the prostate cancer vaccine from Dendreon; Vivus sold the rights to EvaMist, a transdermal estradiol spray, to KV Therapeutics for up to $180 million; Progenics and Wyeth asked the FDA to approve their treatment for opioid-induced constipation; Wyeth also reported that positive results for bifeprunox as a schizophrenia treatment; Astellas Pharma will pay up to $120 million for a non-exclusive license to the VelocImmune technology developed by Regeneron; Galapagos received 3.2 million euros in milestones from GlaxoSmithKline in their osteoarthritis partnership; GlaxoSmithKline also asked for approval of Cervarix, its vaccine for human papillomavirus; and Quark and NovaCardia both filed to make their IPOs. The Centient Biotech 200™ rose 15 points to 3879, an increase of .40%. More details...


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES